Literature DB >> 17549663

Investigation of tissue inhibitor of metalloproteinases 1 in plasma from colorectal cancer patients and blood donors by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.

M B Caspersen1, N M Sørensen, A S Schrohl, P Iversen, H J Nielsen, N Brünner.   

Abstract

Early detection of colorectal cancer (CRC) improves patient survival. Plasma tissue inhibitor of metalloproteinases 1 (TIMP-1) measurements by enzyme-linked immunosorbent assay (ELISA) have been suggested as a new method for the early detection of CRC. To further investigate the nature of TIMP-1 in plasma, surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI TOF MS) was used. TIMP-1 measurements of plasma from 16 healthy donors and 14 CRC patients were performed using TIMP-1 monoclonal antibody in SELDI TOF MS and ELISA. SELDI TOF MS applying an antibody to TIMP-1 revealed that human plasma TIMP-1 has a mass of 25.1 kDa and exhibits several isoforms. Both methods showed increased plasma TIMP-1 values for cancer patients as compared to healthy individuals. The p values for the separation of the groups were 0.0019 for ELISA and <0.0001 for SELDI TOF MS. CRC did not fundamentally affect the appearance of TIMP-1 as evaluated by SELDI TOF MS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17549663     DOI: 10.1177/172460080702200201

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   3.248


  2 in total

1.  Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling.

Authors:  Marie-Christine W Gast; Judith Ymn Engwegen; Jan Hm Schellens; Jos H Beijnen
Journal:  BMC Med Genomics       Date:  2008-01-31       Impact factor: 3.063

2.  Comparative studies of TIMP-1 immunohistochemistry, TIMP-1 FISH analysis and plasma TIMP-1 in glioblastoma patients.

Authors:  Charlotte Aaberg-Jessen; Bo Halle; Stine S Jensen; Sven Müller; Unni Maria Rømer; Christian B Pedersen; Nils Brünner; Bjarne W Kristensen
Journal:  J Neurooncol       Date:  2016-09-12       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.